Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00ARN
|
||||
| Former ID |
DCL000254
|
||||
| Drug Name |
Tyloxapol
|
||||
| Synonyms |
Alevaire; Enuclene; Formaldehyde; Macrocyclon; Oxirane; Superinone; Superiuone; Tiloxapol; Tyloxapolum; Tyloxypal; Component of Alevaire; Superiuone [French]; Triton WR 1339; P-Isooctylpolyoxyethylenephenol formaldehyde polymer; Tiloxapol [INN-Spanish]; Triton A-20; Triton WR-1339; Tyloxapolum [INN-Latin]; Oxyethylated tertiary octyl-phenol-formaldehyde polymer; Triton W.R.1339; Tyloxapol [USAN:BAN:INN]; Ethylene oxide-formaldehyde-p-octylphenol copolymer; P-(1,1,3,3-Tetramethylbutyl)phenol polymer with ethylene oxide and formaldehyde; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetra methylbutyl)phenol; Formaldehyde, polymer with oxirane and 4-(1,1,3,3-tetramethylbutyl)phenol; Phenol, 4-(1,1,3,3-tetramethylbutyl)-, polymer with formaldehyde and oxirane; Phenol, p-(1,1,3,3-tetramethylbutyl)-, polymer with ethylene oxide and formaldehyde; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde & oxirane; 4-(1,1,3,3-Tetramethylbutyl)phenol, polymer with formaldehyde oxirane; 4-(1,1,3,3-tetramethylbutyl)phenol; 4-(2,4,4-trimethylpentan-2-yl)phenol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cystic fibrosis [ICD9: 277; ICD10:E84] | Terminated | [550304] | ||
| Company |
Discovery Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H28O3
|
||||
| Canonical SMILES |
CC(C)(C)CC(C)(C)C1=CC=C(C=C1)O.C=O.C1CO1
|
||||
| InChI |
1S/C14H22O.C2H4O.CH2O/c1-13(2,3)10-14(4,5)11-6-8-12(15)9-7-11;1-2-3-1;1-2/h6-9,15H,10H2,1-5H3;1-2H2;1H2
|
||||
| InChIKey |
MDYZKJNTKZIUSK-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 25301-02-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
R05CA01
|
||||
| Target and Pathway | |||||
| Target(s) | Nuclear factor NF-kappa-B | Target Info | Inhibitor | [537082], [537170] | |
| NetPath Pathway | IL5 Signaling Pathway | ||||
| Pathway Interaction Database | IL12-mediated signaling events | ||||
| Alternative NF-kappaB pathway | |||||
| Reactome | RIP-mediated NFkB activation via ZBP1 | ||||
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||||
| Interleukin-1 processing | |||||
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||||
| IkBA variant leads to EDA-ID | |||||
| Dectin-1 mediated noncanonical NF-kB signaling | |||||
| NIK-->noncanonical NF-kB signaling | |||||
| TRAF6 mediated NF-kB activation | |||||
| WikiPathways | Toll-like receptor signaling pathway | ||||
| DNA Damage Response (only ATM dependent) | |||||
| SIDS Susceptibility Pathways | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Cytosolic sensors of pathogen-associated DNA | |||||
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||||
| EBV LMP1 signaling | |||||
| TNF alpha Signaling Pathway | |||||
| TSLP Signaling Pathway | |||||
| Neural Crest Differentiation | |||||
| TWEAK Signaling Pathway | |||||
| RANKL/RANK Signaling Pathway | |||||
| RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||||
| Interleukin-1 processing | |||||
| Folate Metabolism | |||||
| Vitamin B12 Metabolism | |||||
| Selenium Micronutrient Network | |||||
| Regulation of toll-like receptor signaling pathway | |||||
| References | |||||
| Ref 537082 | Diffusion of an Ionic Drug in Micellar Aqueous Solutions. Langmuir. 2009 Feb 17. | ||||
| Ref 537170 | Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.